Barclays lowered the firm’s price target on Teladoc to $20 from $25 and keeps an Overweight rating on the shares post the Q1 report. The shares were down post the earnings call on a print that featured a headline beat offset by a Q2 guidance miss and steep second half of the year ramp in BetterHelp revenues, the analyst tells investors in a research note. The firm sees a “show me story” but continues to believe in the inherent long term value of Teladoc’s business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Options Volatility and Implied Earnings Moves Today, April 25, 2024
- Optum virtual care exit ‘clear positive’ for Teladoc, says BofA
- UnitedHealth’s Optum closing virtual care business, Endpoints says
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Teladoc Health Provides Updated Start Time for First Quarter 2024 Earnings Call on April 25